Seelos Therapeutics Provides Second Quarter 2023 Clinical Update

- Seelos expects to release top-line data in its registration directed study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation ...

Related Keywords

Massachusetts ,United States ,New York ,California ,Washington ,American ,Anthony Marciano ,Mike Moyer ,Los Angeles ,Lifesci Advisors ,Harvard Medical School At Massachusetts ,Society For Neuroscience ,Nasdaq Hearings Panel ,Prnewswire Seelos Therapeutics Inc ,Seelos Therapeutics Inc ,Access Program ,Nasdaq Stock Market ,Nasdaq ,Exchange Commission ,American Society Of Gene ,National Institute Of Neurological Disorders ,Intranasal Racemic Ketamine ,Acute Suicidal Ideation ,Major Depressive Disorder ,Nasdaq Listing Rule ,Expanded Access Program ,National Institute ,Neurological Disorders ,Accelerating Access ,Critical Therapies ,Harvard Medical School ,Massachusetts General Hospital ,American Society ,Cell Therapy ,Annual Meeting ,Only Mutant Huntingtin Aggregates ,Severe Huntington ,Disease Mice ,Crisis Lifeline ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Sci Advisors ,